Pivotal readout
argenx's VYVGART Hytrulo succeeds in phase 3 autoimmune myositis trial
In ALKIVIA, VYVGART Hytrulo improved the primary score by 15.4 points more than placebo at week 52 across necrotizing myopathy and dermatomyositis. The necrotizing myopathy group reached significance, while the smaller dermatomyositis group did not. argenx aims to file a US supplemental application in necrotizing myopathy by year-end.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.